Related Experiment Video
Updated: May 11, 2026

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
Comorbidity burden in patients with chronic GVHD
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Comorbidity scoring, particularly the HCT-CI, helps predict survival in chronic graft-versus-host disease (cGVHD) patients. Higher scores indicate increased non-relapse mortality, especially with low platelet counts.
Area of Science:
- Hematology
- Transplant Immunology
- Oncology
Background:
- Chronic graft-versus-host disease (cGVHD) significantly impacts patient survival, quality of life, and functional status.
- Understanding comorbidity burden is crucial for accurate prognostication and personalized treatment strategies in cGVHD.
- Existing comorbidity indices require evaluation for their predictive performance in the context of cGVHD.
Purpose of the Study:
- To assess the performance of the Functional Comorbidity Index (FCI) and Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) in predicting outcomes for patients with cGVHD.
- To determine the association between comorbidity scores at cGVHD diagnosis and non-relapse mortality (NRM) and overall mortality.
- To investigate potential interactions between comorbidity scores and clinical factors, such as platelet count, in influencing mortality risk.
Main Methods:
- A prospective cohort study was conducted with 239 patients diagnosed with cGVHD.
- The FCI and HCT-CI were administered at the time of cGVHD cohort enrollment and compared to pre-hematopoietic cell transplant (HCT) assessments.
- Statistical analyses, including hazard ratios (HR), were used to evaluate the association between comorbidity scores and mortality outcomes, considering interactions with platelet count.
Main Results:
- Both FCI and HCT-CI identified a greater number of comorbidities at cGVHD enrollment compared to pre-HCT (P<0.001).
- Higher HCT-CI scores at cGVHD enrollment were significantly associated with increased NRM (HR: 1.21; P=0.01).
- An interaction between HCT-CI and platelet count was observed for overall mortality: higher HCT-CI predicted increased mortality risk when platelet count was ≤ 100,000/μL (HR: 2.01; P=0.01), but not when >100,000/μL (HR: 1.05; P=0.53).
Conclusions:
- Comorbidity scoring, particularly the HCT-CI, is valuable for predicting survival outcomes in patients with cGVHD.
- The HCT-CI demonstrates prognostic utility for both non-relapse mortality and overall mortality, with a notable interaction with platelet count.
- Further research is warranted to explore other factors contributing to vulnerability in cGVHD patients beyond disease activity.
Related Concept Videos
Cytomegalovirus Disease
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Kidney Disease II: Clinical Manifestations
Graves Disease II: Pathophysiology
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Heart Failure III: Clinical Manifestations
